#12 ?? Fear is like a virus and it has penetrated the ?? minds of neophytes and seasoned investors alike.

by Joey Bose and Gaetano Scuderi, MD

The 3-year downturn in the biotech sector has left investors fearful and hesitant to invest in companies with massive growth potential. Now could very well be an ideal moment for entering the biotech investment scene,?seizing stocks at bargain prices?with substantial growth prospects, or placing early bets on private biotechs poised for public market debuts or acquisition deals. This current state of affairs is less about the intrinsic qualities of these companies and more about seizing the moment.?Timing is everything.

?? Simply put, we are in the Golden Age of Biotech…

But it won’t last forever.

The fear is palpable, as investors are nervous to dip their toes back into the biotech sector after the drawn out bear market post-2020. But the tide is shifting, the?pendulum is swinging back in favor of biotech the sector.?

“…be fearful when others are greedy and to be greedy only when others are fearful.”

~?Warren Buffet, CEO of Berkshire Hathaway, Inc. “Chairman’s Letter, 1986.”

Here’s a look at the?XBI biotech index fund, which tracks 100 biotech stocks and is an indicator of the strength of the industry. The pessimistic sentiment is wearing off, and?investors are piling back into the sector in droves.?

This resurgence in confidence is fueled by multiple factors:

• Record number of?new drug approvals?(55) in 2023.
• Big pharma is?flush with cash?and ready to spend (Top 15 pharma companies have a combined?$150B?to spend in 2024).
• Advancement in biotechnology research and development is colliding with a?1 billion person aging population?and the demand for longer, higher quality lifespans.?
• There will?always?be a?demand for advancements in healthcare technology, especially those that extend lifespan and quality of life.?

The????Biotech sector?is still in its infancy, and there is?enormous room for?growth???

Here are some historical examples of what may lay in the future:

• Medivation?rose?11,000%?from 2006 to their acquisition by Pfizer in 2016 for?$14B.
• Celgene?stock has risen more than?30,000%?in two decades.
• Immunomedics?stock grew nearly?9,000%?since 2009.
• Moderna?shares rose more than?4,000%?in a tiny?18 month?window during the pandemic.

All of these stories have one thing in common: they are a?combination of?successful????research and development,????well-timed acquisitions, and????world events.?

All it takes to change your life is?one?well-timed?investment?to begin?generational?wealth?formation ??

Stay tuned for our?next update?in which we will explain why the?Cytonics investment opportunity?could not be?more timely, and why you should have confidence in our ability to advance our drug through clinical trials and create shareholder value.

Ready to become a shareholder? Visit invest.cytonics.com.

This communication?may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events based information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they contain hypothetical illustrations of mathematical principles, are meant for illustrative purposes, and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results.